A federal appeals court upheld two patents for Amgen’s multibillion-dollar rheumatoid arthritis drug Enbrel, rejecting Novartis’ effort to void the patents.

A Missouri appeals court rejected Johnson & Johnson’s bid to throw out a jury verdict in favor of women who blamed their ovarian cancer on the company’s baby powder and other talc products, but reduced its damages award to $2.12 billion from $4.69 billion.

A U.S. district court ruled in favor of generic drugmaker Mylan NV in a patent dispute over Biogen Inc.’s blockbuster multiple sclerosis drug Tecfidera, sending Biogen’s shares down nearly 6 percent.

A federal appeals court revived nationwide litigation accusing Roche Holding AG’s Genentech unit of failing to ensure that vials of the comapny’s Herceptin breast cancer drug contained the labeled amount of the active ingredient, and that the labels misstated the drug’s concentration and volume.

Shares of Amarin Corporation were down more than 70 percent in trading after a judge ruled that generic companies can go ahead and seek approval of generic versions of the drug manufacturer’s heart disease drug Vascepa.

Florida-based Catalyst Pharmaceuticals is attempting to show in court that the price of a newly approved treatment for a rare autoimmune disease and pressure from U.S. Sen. Bernie Sanders lead to the approval of a rival treatment.

John Kapoor, the founder of Insys Therapeutics Inc., could be sentenced to several years in prison and ordered to forfeit up to $113 million for his role in a bribery and fraud scheme that contributed to the U.S. opioid crisis.

One year after his arrest, PixarBio CEO Francis Reynolds was convicted of defrauding investors of $12.7 million.

Baxter International Inc. was named in a complaint for improperly marketing opioid drugs and revealed an internal probe into the medical supplier’s accounting, sending the company’s shares down.

A Missouri appeals court overturned a $110 million verdict against Johnson & Johnson in a lawsuit by a Virginia woman who says she developed ovarian cancer after decades of using of the company’s talc-based products for feminine hygiene.